Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients.

Date publication

février 2026

Journal

Advances in therapy

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier

Tous les auteurs :
Girard N, Macouillard P, Byng D, Meng J, Coerts F, Hunter S, Struebing A, Xiong Y, Park S, Haq MI, Tymejczyk O, Chouaid C, Audigier-Valette C, Debieuvre D, Quantin X, Bosquet L, Pérol M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41686417

Résumé

Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), is a standard first-line (1L) treatment for advanced/metastatic EGFR non-small cell lung cancer (NSCLC). Despite improved overall survival (OS) and progression-free survival (PFS) compared to earlier generation TKIs, resistance and disease progression are common. No standardized second-line (2L) treatment exists for patients who progress after 1L osimertinib. This study assessed real-world (rw) treatment patterns and clinical outcomes in French patients with advanced/metastatic NSCLC who received 2L therapy post-osimertinib progression.

Mots clés

EGFR, NSCLC, Osimertinib, Overall survival, Platinum-based chemotherapy, Progression-free survival, Real-world, Tyrosine kinase inhibitors

Référence

Adv Ther. 2026 02 13;: